In an announcement on 29 September 2026, AstraZeneca set out two linked agreements with Summit Therapeutics Inc. The first is a $2bn strategicInvestmentin newly issued Summit stock. The second is a clinical collaboration to test Sone-Ve with ivonescimab in gastrointestinal cancers.
Oxford BioMedica is a specialist cell-and-gene-therapy contract development andManufacturingorganisation. ItsInvestmentcase is linked to theLong-term Growthof advanced therapies and the increasing need for specialist manufacturing capacity. First-half 2026 results showed 10% constant-currency revenue growth to £80.2 million, while management reiterated full-year and medium-term guidance.
Spire Healthcare —LSE:SPI— is attracting attention as its proposed acquisition moves into another important stage.
Coiled Therapeutics —LSE:COIL— is attracting attention after publishing its latest interim results, giving investors an updated view of its financial position and progress across its gene-editing pipeline.
AstraZeneca —LSE:AZN— has moved into focus following its agreement to invest$2 billion in newly issued equity of Summit Therapeutics.
Venture Life released final results on 29 September 2026 for the 17-month period ended 31 May 2026 and also announced a chief executive succession. Earlier trading information indicatedRevenueof £50.0 million for the period, up 30.9%, with pro-forma growth of 16.0%. In the final five …
Nuformix (LSE:NFX) describes itself as a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology through drug repurposing, developing new formulations of existing compounds with improved properties. Its shares trade on theLondon Stock ExchangeMain Market under the code NFX. The company's lead …
Avacta (LSE:AVCT) describes itself as a clinical-stage life sciences company developing targeted cancer therapies. Its pre|CISION technology attaches a potent chemotherapy payload to a peptide that is cleaved by fibroblast activation protein (FAP), an enzyme found in high concentrations in the tumour microenvironment. The …
Oxford BioDynamics, spun out of the University of Oxford in 2007, develops blood tests and research tools built on EpiSwitch, a proprietary platform that maps the three-dimensional architecture of the genome. Its commercial tests include the PSE test for prostate cancer detection and CiRT, …
The company invests in global healthcare stocks. It was previously known as Bellevue Healthcare Trust plc, and according to its change-of-name announcement of 24 March 2026, it adopted the CT Healthcare Trust name with effect from 19 March and began trading on the Main …